Fortrea Holdings Reports Q2 2026 Revenue of $678.2 Million, Operating Income Improvement

Fortrea Holdings Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $678.2 million, a decrease of 4.5% from $710.3 million in the same period last year. For the first half of 2026, revenues totaled $1.314 billion, down 3.4% from $1.362 billion in the first half of 2025. The decline in revenue was attributed to a 4.9% decrease in organic revenues, primarily due to lower demand in the functional service provider business and reduced pass-through costs, although this was partially offset by growth in the clinical pharmacology segment.

The company's operating income for the second quarter was $14.8 million, a significant improvement from a loss of $330.3 million in the prior year. For the first half of 2026, Fortrea reported an operating income of $11.4 million, compared to a loss of $850.4 million in the same period of 2025. The improvement in profitability was largely due to a reduction in total costs and expenses, which fell to $663.4 million from $1.041 billion year-over-year, aided by a decrease in direct costs and selling, general, and administrative expenses.

In terms of strategic developments, Fortrea has been actively managing its operations following its spin-off from Labcorp in June 2023. The company has streamlined its workforce and reduced costs, resulting in a 73.8% decrease in restructuring charges for the second quarter compared to the previous year. Additionally, Fortrea's backlog stood at $7.8 billion as of June 30, 2026, indicating a strong pipeline of future business opportunities. The company continues to leverage its global presence, with operations in approximately 100 countries and a workforce of around 14,000 employees.

Geographically, Fortrea's revenue distribution for the second quarter showed North America contributing $319.7 million, Europe $219.7 million, and other regions $138.8 million. The company has also engaged in a receivables securitization program, selling $300 million of receivables to enhance liquidity. As of June 30, 2026, Fortrea had cash and cash equivalents of $168.6 million, a decrease from $174.6 million at the end of 2025, reflecting ongoing investments in growth and operational efficiency.

Looking ahead, Fortrea's management expressed optimism about future performance, citing expectations for continued growth in its clinical pharmacology business and a focus on strategic investments to enhance operational capabilities. The company remains committed to navigating market challenges while capitalizing on opportunities in the biopharmaceutical development sector.